Impact of Daily Low-Dose Tadalafil in Patients With Acute Peyronie's Disease: A Retrospective Comparative Analysis of Clinical Outcomes

doi:10.21203/rs.3.rs-1979160/v1

Download PDF

Article

Impact of Daily Low-Dose Tadalafil in Patients With Acute Peyronie's Disease: A Retrospective Comparative Analysis of Clinical Outcomes

https://doi.org/10.21203/rs.3.rs-1979160/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 13 Dec, 2022

Read the published version in International Journal of Impotence Research →

You are reading this latest preprint version

The aim of this study was to evaluate the clinical outcomes of patients in acute phase of Peyronie’s disease (PD) treated with daily low-dose of Tadalafil. An observational retrospective study involving patients in acute phase of PD with erectile dysfunction (ED) was designed. All subjects were offered Tadalafil 5 mg one tablet a day. Men who accepted treatment were compared to patients who refused Tadalafil. Penile curvature progression was chosen as the primary outcome. PD Questionnaire (PDQ) and IIEF-5 scores were selected as secondary outcomes. A total of 191 patients were included in the study (108 intervention vs. 83 control). Penile curvature progression rate was significantly lower in subjects taking Tadalafil at 12 weeks (25.9% vs 39.7%, p = 0.042). Mean IIEF-5 score improved in the intervention group, becoming significantly higher compared to the observation group at 12 weeks (19.3 vs. 11.2 points, p < 0.001). Mean PDQ-Overall and PDQ-Penile Pain scores improved in the intervention group and the statistically significant differences at baseline between groups became not statistically significant at 12 weeks (p = 0.232 and p = 0.078, respectively). Daily low-dose Tadalafil in patients with acute phase of PD seems to significantly reduce the penile curvature progression rate compared to observation, especially when it is administrated early. It also appears to improve erectile function and PD-related symptoms.

Peyronie’s disease (PD) is an acquired disorder involving the connective tissue of the tunica albuginea of the corpora cavernosa characterized by the formation of fibrous plaques that alter penile anatomy [1]. PD consists of two successive phases. The first is an acute inflammatory phase typically, but not invariably, characterized by palpable fibrous plaque, progressive penile curvature and pain during erection. This stage can last up to 12–18 months. The second is a chronic stable phase in which the penile curvature stabilizes, the pain disappears, and the plaque calcifies [2, 3]. About 48% of men with PD suffer from depression [4]. Moreover, approximately 32% of untreated PD patients complain of some degree of erectile dysfunction (ED) [5]. Other reports have suggested that the prevalence of ED in PD patients may be up to 80% [6]. Currently, an etiological therapy for PD is not available. Conservative and surgical treatments can be distinguished [7, 8]. Conservative therapy should be offered to patients in the acute phase and men in the chronic phase who are unwilling or unable to undergo surgery [9]. During the acute phase nonsteroidal anti-inflammatory drugs (NSAIDs) and extracorporeal shockwave treatment (ESWT) may be administrated to relieve penile pain, while the evidence supporting conservative treatments capable of acting on the progression of penile curvature is still limited [9, 10]. Phosphodiesterase 5 inhibitors (PDE5Is) represent the first-line treatment for ED [11, 12]. Interestingly, some preclinical evidence demonstrated the antifibrotic effects of PDE5Is in PD models [13]. Besides, some preliminary studies highlighted the potential antifibrotic and analgesic effects of PDE5Is in men with PD [14, 15]. Accordingly, long-term treatment with PDE5Is could represent an emerging strategy for conservative treatment of PD [16]. However, current European Association of Urology (EAU) Guidelines still recommend the use of PDE5Is only to improve the erectile function of PD patients [9]. In fact, although the use of these drugs in patients with PD is progressively increasing, there is still little clinical evidence demonstrating their effectiveness in reducing symptoms and disease progression [17].

The aim of this study was to evaluate the clinical outcomes of patients in acute phase of PD treated with daily low-dose of Tadalafil.

Study design and Ethical aspects

We designed an observational retrospective study involving PD patients referring to the outpatient clinic of our tertiary center (Urology Unit, University of Naples “Federico II”, Naples, Italy) from September 2018 to March 2020. A prospectively maintained anonymous database was used to collect all data. The research was conducted in accordance with the Declaration of Helsinki on ethical principles for medical research involving human subjects [18]. All patients gave a written informed consent for collection and publication of their clinical data. Given the purely observational retrospective nature of the study, no approval was required from the Ethics Committee.

Patient enrollment and Treatment protocol

Male patients, over 18 years old, in acute phase of PD, with a penile curvature < 30 degrees, complaining of ED were included in the study. Acute phase of PD was defined as progressive worsening of penile curvature associated with penile pain during erection, regardless of the time from the onset of symptoms. ED was defined as five-item version of International Index of Erectile Function (IIEF-5) score < 22 [19]. All patients were sexually active (at least 1 sexual intercourse per month in the past 3 months) and had a stable partner (single sexual partner in the past 3 months). The followings were considered exclusion criteria: previous treatments specifically targeted to PD, previous daily use of PED5Is or intracavernous vasoactive agents for ED, concomitant penile disorders, complex penile deformities (hinge or hourglass), history of pelvic surgery or radiotherapy. Intake of nitrates, severe heart diseases, non-arteritic anterior ischemic optic neuropathy (NAION), and other conditions that contraindicated the intake of PDE5Is were further reasons for exclusion.

All patients who met the above criteria were offered Tadalafil 5 mg one tablet a day at the same time regardless of meals for 12 weeks. Men who accepted treatment (intervention group) were compared to patients who refused PDE5Is and any other form of conservative treatment for personal reasons (observational group). Patients in the intervention group underwent no other conservative treatment for PD. Only subjects with a complete 12-week follow-up and who did not discontinue Tadalafil treatment were included in the analysis.

Patient evaluation and Selected outcomes

The following data were collected for each patient at baseline: age, body mass index (BMI), diabetes mellitus, smoking, hypertension, dyslipidemia, total serum testosterone, time from onset of symptoms, plaque features, penile curvature, PD Questionnaire (PDQ) [20], and IIEF-5.

Penile curvature assessment was performed by a single experienced urologist following intracavernous injection of 10 micrograms of alprostadil and using a goniometer. The study of penile plaques was performed with ultrasonography. IIEF-5 and PDQ were self-administrated to patients.

Penile curvature, PDQ, and IIEF-5 were reassessed after 12 weeks in both groups. Penile curvature progression was chosen as the primary outcome and was arbitrarily defined as worsening of curvature after 12 weeks ≥ 10 degrees. In the case of mixed penile curvatures, the greater one was taken into account. PDQ and IIEF-5 scores were selected as secondary outcomes. All adverse events (AEs) were recorded in the follow-up period.

Statistics

The categorical variables were described as frequencies and percentages. The continuous variables were expressed as mean ± standard deviation (SD). The Kolmogorov-Smirnov test was applied as normality test [21]. The Student’s t-test and the Chi-squared test were used to compare continuous and categorical variables, respectively [22]. Statistical significance was set a priori at p ≤ 0.05. A sub-analysis was performed according to the duration of the disease based on an arbitrary cut-off (≤ 9 months vs > 9 months). The IBM Statistical Package for the Social Sciences (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.) was used for the statistical analyses.

A total of 191 patients were included in the study, 108 received Tadalafil and 83 underwent observation. Mean (SD) age was 59.0 (9.0) years in the intervention group and 57.7 (9.2) years in the observation group (p = 0.442). Mean (SD) time from onset of PD was 9.8 (5.5) and 10.9 (6.7) months (p = 0.232), for the intervention and observation group, respectively. Most penile curvatures were dorsal in both groups (46.2% vs. 48.2%). Mean (SD) penile curvature at baseline was 19.0 (7.8) degrees in patients treated with Tadalafil and 18.0 (7.5) degrees in controls (p = 0.265). Baseline demographic and clinical characteristics of both groups were detailed in Table 1.

Table 1

Demographic and clinical characteristics of patients in both groups
	Tadalafil (n = 108)	Observation (n = 83)	p-value
Age, years Mean (SD)	59.0 (9.0)	57.7 (9.2)	0.442
BMI, kg/m² Mean (SD)	28.9 (5.7)	28.5 (6.0)	0.651
Diabetes mellitus n (%)	18 (16.6)	5 (6.0)	0.012
Hypertension n (%)	10 (9.2)	22 (26.5)	0.001
Dyslipidemia n (%)	18 (16.6)	13 (15.6)	0.852
Smoking n (%)	52 (48.1)	22 (26.5)	0.034
Total serum testosterone, n/dL Mean (SD)	311.3 (129.9)	383.2 (162.4)	0.001
Time from onset, months Mean (SD)	9.8 (5.5)	10.9 (6.7)	0.232
Time from onset, n (%) - ≤ 9 months - > 9 months	56 (51.8) 52 (47.2)	37 (44.5) 46 (55.4)	0.318
Penile curvature angle, degrees Mean (SD)	19.0 (7.8)	18.0 (7.5)	0.265
Penile curvature direction, n (%) - Dorsal - Lateral - Ventral - Mixed	50 (46.2) 22 (20.4) 8 (7.4) 28 (25.9)	40 (48.2) 15 (18.0) 6 (7.2) 22 (26.5)	0.310
Major plaque volume, cc Mean (SD)	3.1 (0.7)	2.6 (1.0)	0.128
Major plaque calcification, n (%)	40 (37.0)	25 (30.1)	0.317
IIEF-5, points Mean (SD)	15.6 (4.8)	13.1 (5.0)	0.211
PDQ, points Mean (SD) - Overall - PPS - PP - SB	43.1 (13.5) 15.5 (5.7) 17.9 (6.6) 8.7 (3.3)	33.0 (13.7) 12.4 (6.3) 12.9 (6.2) 7.6 (4.8)	0.001 0.059 < 0.001 0.070
BMI: Body Mass Index; IIEF-5: Five-item version of International Index of Erectile Function; PDQ: Peyronie’s Disease Questionnaire; PPS: Psychological and Physical Symptoms; PP: Penile Pain; SB: Symptom Bother; SD: Standard Deviation.

Penile curvature progression rate was significantly lower in subjects taking Tadalafil than men under observation at 12 weeks (25.9% vs 39.7%, p = 0.042). This statistically significant difference was maintained in patients with a time from onset of PD ≤ 9 months (p = 0.003), in contrast to the subgroup characterized by time from onset > 9 months (p = 0.059). Penile curvature angle and progression rate according to treatment and duration of disease were reported in Table 2 and Fig. 1, respectively.

Table 2

Penile curvature (degrees) according to treatment and PD duration
	Total		≤ 9 months		> 9 months
	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)
Tadalafil	19.0 (7.8)	20.8 (11.8)	21.3 (9.7)	22.9 (10.7)	19.0 (6.8)	22.7 (10.0)
Observation	18.0 (7.5)	28.1 (13.7)	19.4 (7.3)	28.8 (13.6)	18.5 (7.8)	25.2 (12.7)
p-value	0.265	0.044	0.348	0.003	0.618	0.059
PD: Peyronie’s Disease; SD: Standard Deviation.

Mean IIEF-5 score significantly improved (p = 0.001) in the intervention group, becoming significantly higher compared to the observation group at 12 weeks (19.3 vs. 11.2 points, p < 0.001). IIEF-5 score was described in Table 3. Mean PDQ-Overall and PDQ-Penile Pain (PDQ-PP) scores significantly improved (p < 0.001) in the intervention group and the statistically significant differences in favor of the observation group at baseline became not significant at 12 weeks (p = 0.232 and p = 0.078, respectively). PDQ-Overall and PDQ-PP scores were summarized in Table 4.

Table 3

IIEF-5 score (points) according to treatment and PD duration
	Total		≤ 9 months		> 9 months
	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)
Tadalafil	15.6 (4.8)	19.3 (3.7)	16.5 (4.9)	20.0 (4.0)	14.6 (4.5)	18.7 (3.3)
Observation	13.1(5.0)	11.2 (5.2)	14.7 (4.5)	11.1 (4.9)	13.5 (5.5)	11.4 (5.5)
p-value**	0.211	< 0.001	0.089	< 0.001	0.067	< 0.001
IIEF-5: Five-item version of International Index of Erectile Function; PD: Peyronie’s Disease; SD: Standard Deviation.

Table 4

PDQ scores (points) according to treatment and PD duration
PDQ-Overall
	Total		≤ 9 months		> 9 months
	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)
Tadalafil	43.1 (13.5)	33.2 (10.9)	41.2 (14.1)	32.9 (10.7)	40.9 (14.0)	33.2 (11.3)
Observation	33.0 (13.7)	35.1 (13.7)	31.8 (13.9)	34.0 (12.6)	34.4 (12.8)	34.5 (12.2)
p-value	0.001	0.232	0.006	0.311	0.022	0.098
PDQ-PPS
	Total		≤ 9 months		> 9 months
	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)
Tadalafil	15.5 (5.7)	12.1 (5.4)	13.8 (6.6)	13.2 (3.6)	15.3 (3.8)	10.9 (5.5)
Observation	12.4 (6.3)	12.4 (6.3)	12.5 (6.6)	12.8 (6.6)	12.5 (6.6)	12.0 (6.2)
p-value	0.059	0.360	0.055	0.282	0.061	0.155
PDQ-PP
	Total		≤ 9 months		> 9 months
	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)
Tadalafil	17.9 (6.6)	12.3 (4.7)	16.1 (7.7)	14.7 (6.6)	17.8 (4.6)	14.2 (6.4)
Observation	12.9 (6.2)	13.0 (6.4)	13.1 (6.3)	13.2 (2.6)	12.7 (6.2)	12.4 (6.1)
p-value	< 0.001	0.078	< 0.001	0.343	< 0.001	0.069
PDQ-SB
	Total		≤ 9 months		> 9 months
	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)	Baseline Mean (SD)	12 weeks Mean (SD)
Tadalafil	8.7 (3.3)	8.0 (3.2)	7.8 (3.7)	8.8 (2.6)	9.7 (2.6)	7.4 (3.6)
Observation	7.6 (4.8)	7.7 (4.8)	5.5 (5.0)	9.0 (4.0)	9.3 (3.8)	5.7 (5.1)
p-value	0.070	0.066	0.053	0.134	0.884	0.058
PD: Peyronie’s Disease; PDQ: Peyronie's Disease Questionnaire; PDQ-PPS: PDQ-Psychological and Physical Symptoms; PDQ-PP: PDQ-Penile Pain; PDQ-SB: PDQ-Symptom Bother; SD: Standard Deviation.

Only mild AEs (e.g., headache, flushing, dyspepsia, nasal congestion) were recorded in a minority of cases (19, 17.6%) belonging to the Tadalafil group.

A conservative therapy is frequently advocated in the acute phase of PD to relieve the penile pain or prevent the progression of penile curvature, but the evidence on the topic is still limited. PDE5Is are part of the conservative management of patients with PD, however, they are traditionally used to improve erection in this population [23]. In recent years, preliminary evidence, first in animal models and in vitro and subsequently in humans, have highlighted the antifibrotic and analgesic potential of long-term administration of PDE5Is in PD [15, 24, 25].

Clinical evidence on PDE5Is in PD patients

A recent survey of 401 sexual medicine experts across Europe found that the most common oral medication prescribed for the treatment of PD was Tadalafil 5 mg once daily (57.4%) [16]. Palmieri et al. showed in a randomized controlled trial (RCT) on PD patients complaining of ED that ESWT plus Tadalafil 5 mg once daily significantly improved IIEF-5 and quality of life (QoL) compared to ESWT alone at 6 months [3]. Dell’Atti compared intralesional verapamil injection (IVI), Tadalafil 5 mg daily, and IVI plus Tadalafil 5 mg daily in a 3-month RCT on PD patients. Penile pain resolved completely or partially in 57%, 61%, and 76% of cases, respectively. A slight reduction in penile curvature was recorded in all groups with no significant differences compared to baseline. Plaque size remained stable in IVI alone and Tadalafil alone groups, significantly decreasing in the combination group. IIEF-5 significantly improved in Tadalafil alone and combination groups, with a statistically significant difference in favor of the latter [26]. Hatampour et al. compared intraplaque injection of dexamethasone plus Tadalafil 5 mg once daily and IVI in another 3-month RCT on chordee patients with PD. Degree of penile curvature, plaque count, and plaque size decreased significantly in both groups from baseline, with no significant difference between the groups [27]. Chung et al. evaluated PD patients with septal scars undergoing Tadalafil 2.5 mg daily over a 6-month period in a retrospective controlled study. The Tadalafil group reported a significantly higher IIEF-5 score and significantly more frequent septal scar resolution than the control group. Besides, 5 patients in the control group and only 1 subject in the Tadalafil group showed worsening or penile curvature during the follow-up [14]. Ozturk et al. compared Sildenafil 50 mg daily and Vitamin E 400 IU daily in a RCT with 3 months of follow-up. IIEF-5, penile curvature, plaque volume, and pain score were significantly improved from baseline in the Sildenafil group. Moreover, the improvements in IIEF-5 score and pain score were statistically significant in Sildenafil group compared with Vitamin E group [15].

Molecular mechanisms of PDE5Is in PD

Several studies on fibrosing diseases (e.g., idiopathic pulmonary fibrosis, Duchenne muscular dystrophy, cardiac and renal fibrosis) showed that PDE5Is have antifibrotic properties [28]. Growing evidence is showing that continuous therapy with PDE5Is may block or reverse fibrosis of the corpora cavernosa and tunica albuginea, with antifibrotic mechanisms independent of the well-known effect of vasodilation and increased blood flow associated with these drugs. Continuous PDE5Is administration induces a sustained elevation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) in the penile tissues. This pathway, probably by activating protein kinase G (PKG), leads to decrease profibrotic factor secretion (e.g., TGF-β1), myofibroblasts count, and collagen deposition [13]. Myofibroblasts are “the most intensive collagen factory”. Oxidative stress and inflammation typical of the acute phase of PD promote local fibroblast-to-myofibroblast conversion. Sustained levels of NO and cGMP seems hinder this differentiation and promote myofibroblast apoptosis. The timing for the administration of PDE5Is could be essential, a recent study suggests that these drugs can prevent but not reverse myofibroblast transformation, therefore, they should only be used in the early stage of PD for antifibrotic purposes [29]. However, the antifibrotic mechanisms of PDE5Is in the penile tissues are probably still largely unknown and some of them could be partially or totally independent from the NO/cGMP pathway. Finally, we hypothesize that an anti-inflammatory and antioxidant effect of continuous PDE5Is may contribute to the reduction of penile pain in patients with PD, however this statement is not currently supported by solid biomolecular evidence [24, 25, 30].

Our main findings

In this study we compared the clinical outcomes of PD patients receiving Tadalafil 5 mg daily or observation. Interestingly, we found that the penile curvature progression rate was significantly lower in patients taking Tadalafil than men under observation (p = 0.042). This finding supports the hypothesis that PDE5Is may interfere with the pathogenesis of fibrosis in PD patients [31]. Moreover, the difference between the two groups was significant (p = 0.002) only when considering patients with short duration of the disease (≤ 9 months). This result suggests a substantial benefit especially when therapy with PDE5Is is started early.

Furthermore, in patients receiving Tadalafil we observed a predictable significant improvement in the IIEF-5 score and statistically significant higher scores compared to subjects in the observation group. This finding aligns with the recommendation of the EAU guidelines to offer PDE5Is to PD patients to improve erection and optimize penetration [9].

Finally, we found a significant improvement in the PDQ-Overall and PDQ-PP scores of men treated with Tadalafil and stable scores in observed patients. Consequently, despite a statistically significant difference at baseline in favor of the observation group, no statistically significant differences were recorded between the two groups at 12 weeks. This result supports previous evidence on the analgesic effect of PDE5Is in PD patients [15].

Strengths and Limitations

To the best of our knowledge this is the first study specifically designed to evaluate the clinical outcomes of patients in acute phase of PD treated with Tadalafil 5 mg daily alone. Furthermore, despite the relatively small sample size, this is to date the clinical study on the topic with the largest cohort of patients evaluated. Other significant strengths of this paper are the well-defined methodology, the presence of a comparative group, and the use of validated tools for measuring outcomes. However, our research should be read and interpreted considering various issues. The main limitation is the retrospective design. Another weakness, caused by the lack of randomization, is the presence of some significant differences at baseline between the intervention and observation group. There is no univocal definition of penile curvature progression, therefore it was decided arbitrarily, this may have influenced the direction of the results. The course of PD is unpredictable and especially for patients with time from onset > 9 months the improvement in clinical outcomes could be due in part to spontaneous disease stabilization rather than PDE5Is [31]. Only men with penile pain and progressive worsening of the penile curvature were included in the study, but it is known that a significant proportion of subjects in the acute phase of PD may have no pain or progression of the curvature [32]. In addition, the selected patients had overall a mild penile curvature and all complained of ED. Finally, only men who had not discontinued Tadalafil treatment were included, although it is known that not negligible percentage of patients treated with PDE5Is may discontinue therapy for various reasons [22, 33]. These last three issues could hinder the generalizability of our results. Noteworthy is that a relevant number of men included had calcified plaques, suggesting that, despite the symptoms, some subjects were closer to stabilizing the disease. However, the concept of calcified plaque as a pathognomonic sign of stable disease is currently under discussion and there was no significant difference between the intervention and observation groups regarding the presence of calcified plaques [34].

Daily low-dose Tadalafil in patients with acute phase of PD seems to significantly reduce the penile curvature progression rate compared to observation, especially when it is administrated early. Besides, it appears to improve erectile function and PD-related symptoms. However, the results of the present study should be considered preliminary due to its significant limitations. Further well-designed RCTs are needed to confirm our promising findings.

Author Contributions

Conceptualization: LS, CM; Data Collection: RLR, LN, ADA, MC; Data analysis: FT, CS; Writing-original draft: LS, CM; Scientific review: IS; Supervision: MC, DA.

Data availability

Raw data is available if requested.

Acknowledgments

None.

Conflict of interests

The authors declare no conflict of interest.

Founding

The authors declare no founding.

Miner MM, Seftel AD. Peyronie’s disease: epidemiology, diagnosis, and management. Curr Med Res Opin. gennaio 2014;30(1):113–20.
Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A First Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Extracorporeal Shock Wave Therapy for the Treatment of Peyronie’s Disease. Eur Urol. agosto 2009;56(2):363–70.
Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial: ESWT and Tadalafil in PD patients. Int J Androl. aprile 2012;35(2):190–5.
Nelson CJ, Mulhall JP. Psychological Impact of Peyronie’s Disease: A Review. J Sex Med. marzo 2013;10(3):653–60.
Mulhall JP, Schiff J, Guhring P. An Analysis of the Natural History of Peyronie’s Disease. J Urol. giugno 2006;175(6):2115–8.
Weidner W, Schroeder-Printzen I, Weiske WH, Vosshenrich R. Sexual Dysfunction in Peyronie’s Disease: An Analysis of 222 Patients Without Previous Local Plaque Therapy. J Urol. gennaio 1997;157(1):325–8.
Capece M, Arcaniolo D, Manfredi C, Palmieri A, De Sio M, Verze P, et al. Second cycle of intralesional Collagenase Clostridium histolyticum for Peyronie’s disease using the modified shortened protocol: Results from a retrospective analysis. Andrologia [Internet]. aprile 2020 [citato 3 luglio 2022];52(3). Disponibile su: https://onlinelibrary.wiley.com/doi/10.1111/and.13527
Fernández-Pascual E, Manfredi C, Cocci A, Quintana Franco LM, Egui Rojo MA, Carballido Rodríguez J, et al. A Novel Penile Splint as Early Traction Therapy After Grafting Techniques for Peyronie’s Disease. J Sex Med. settembre 2020;17(9):1819–24.
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology Guidelines on Sexual and Reproductive Health—2021 Update: Male Sexual Dysfunction. Eur Urol. settembre 2021;80(3):333–57.
Manfredi C, Arcaniolo D, Amicuzi U, Spirito L, Napolitano L, Crocerossa F, et al. Impact of extracorporeal shockwave therapy for erectile dysfunction and Peyronie’s disease on reproductive and hormonal testicular function. Andrology. 17 agosto 2022;andr.13240.
Zucchi A, Costantini E, Scroppo FI, Silvani M, Kopa Z, Illiano E, et al. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. Andrology. novembre 2019;7(6):804–17.
Mirone V, Napolitano L, D’Emmanuele di Villa Bianca R, Mitidieri E, Sorrentino R, Vanelli A, et al. A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation. Arch Ital Urol E Androl. 28 giugno 2021;93(2):221–6.
Gonzalez-Cadavid NF, Rajfer J. Laboratory Forum: Experimental Models of Peyronie’s Disease. Implications for New Therapies. J Sex Med. febbraio 2009;6(2):303–13.
Chung E, DeYoung L, Brock GB. The Role of PDE5 Inhibitors in Penile Septal Scar Remodeling: Assessment of Clinical and Radiological Outcomes. J Sex Med. maggio 2011;8(5):1472–7.
Ozturk U, Yesil S, Goktug HNG, Gucuk A, Tuygun C, Sener NC, et al. Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci 1971 -. settembre 2014;183(3):449–53.
Porst H, Burri A. Current Strategies in the Management of Peyronie’s Disease (PD)—Results of a Survey of 401 Sexual Medicine Experts Across Europe. J Sex Med. giugno 2019;16(6):901–8.
Teloken, Katz. Medical Management of Peyronie’s Disease: Review of the Clinical Evidence. Med Sci. 18 settembre 2019;7(9):96.
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 27 novembre 2013;310(20):2191.
Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 1 agosto 2002;14(4):245–50.
Coyne KS, Currie BM, Thompson CL, Smith TM. Responsiveness of the Peyronie’s Disease Questionnaire (PDQ). J Sex Med. aprile 2015;12(4):1072–9.
Aslam M. Introducing Kolmogorov–Smirnov Tests under Uncertainty: An Application to Radioactive Data. ACS Omega. 14 gennaio 2020;5(1):914–7.
Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher’s exact test. Restor Dent Endod. 2017;42(2):152.
Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T Peer-Rev J Formul Manag. luglio 2013;38(7):407–19.
Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, et al. Antifibrotic Role of Inducible Nitric Oxide Synthase. Nitric Oxide. maggio 2002;6(3):283–94.
Valente EGA, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. dicembre 2003;9(4):229–44.
Dell′Atti L. Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie′s disease. Urol Ann. 2015;7(3):345.
Hatampour M, Sohrabi K, Mazdak H, Ghadimi K, Salehi H, Kazemi R. Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease. Am J Clin Exp Urol. 2022;10(1):25–30.
Gong W, Yan M, Chen J, Chaugai S, Chen C, Wang D. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling. Front Med. dicembre 2014;8(4):445–55.
Ilg MM, Stafford SJ, Mateus M, Bustin SA, Carpenter MJ, Muneer A, et al. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie’s Disease. J Sex Med. ottobre 2020;17(10):1848–64.
Gonzalez-Cadavid NF, Rajfer J. The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent. A personal perspective. Int J Impot Res. marzo 2019;31(2):57–60.
Garaffa G, Trost LW, Serefoglu EC, Ralph D, Hellstrom WJG. Understanding the course of Peyronie’s disease. Int J Clin Pract. agosto 2013;67(8):781–8.
Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res. 1 ottobre 2002;14(5):414–7.
Verze P, Capece M, Creta M, La Rocca R, Persico F, Spirito L, et al. Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl. 2020;22(4):379.
Hussein AA, Alwaal A, Lue TF. All about Peyronie’s disease. Asian J Urol. aprile 2015;2(2):70–8.

There is NO conflict of interest to disclose.

Download PDF

Journal Publication

published 13 Dec, 2022

Read the published version in International Journal of Impotence Research →

Editorial decision: revise
26 Sep, 2022
Review #3 received at journal
18 Sep, 2022
Review #2 received at journal
11 Sep, 2022
Reviewer #3 agreed at journal
07 Sep, 2022
Review #1 received at journal
05 Sep, 2022
Reviewer #2 agreed at journal
28 Aug, 2022
Reviewer #1 agreed at journal
27 Aug, 2022
Reviewers invited by journal
27 Aug, 2022
Submission checks completed at journal
22 Aug, 2022
Editor assigned by journal
19 Aug, 2022
First submitted to journal
19 Aug, 2022

You are reading this latest preprint version

Impact of Daily Low-Dose Tadalafil in Patients With Acute Peyronie's Disease: A Retrospective Comparative Analysis of Clinical Outcomes

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Materials And Methods

Study design and Ethical aspects

Patient enrollment and Treatment protocol

Patient evaluation and Selected outcomes

Statistics

Results

Discussion

Clinical evidence on PDE5Is in PD patients

Molecular mechanisms of PDE5Is in PD

Our main findings

Strengths and Limitations

Conclusions

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 1